Have a feature idea you'd love to see implemented?
Let us know!
INZY Inozyme Pharma Inc
Price (delayed)
$4.9
Market cap
$307.4M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.46
Enterprise value
$338.56M
Inozyme Pharma is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization. Through the company's in-depth understanding of the biological pathways involved in
Highlights
INZY's EPS is down by 7% since the previous quarter but it is up by 6% year-on-year
The company's debt rose by 37% YoY
The quick ratio has contracted by 31% from the previous quarter and by 20% YoY
Key stats
What are the main financial stats of INZY
Market
Valuations
Earnings
Shares outstanding
62.73M
Market cap
$307.4M
Enterprise value
$338.56M
Price to earnings (P/E)
N/A
Price to book (P/B)
3.21
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$82.51M
EBITDA
-$81.19M
Free cash flow
-$85.69M
Per share
Balance sheet
Liquidity
EPS
-$1.46
Free cash flow per share
-$1.38
Book value per share
$1.53
Revenue per share
$0
TBVPS
$2.51
Total assets
$155.71M
Total liabilities
$61.29M
Debt
$46.71M
Equity
$94.42M
Working capital
$137.42M
Debt to equity
0.49
Current ratio
9.84
Quick ratio
9.32
Net debt/EBITDA
-0.38
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-47.9%
Return on equity
-68.9%
Return on invested capital
-44.6%
Return on capital employed
-58.9%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
INZY stock price
How has the Inozyme Pharma stock price performed over time
Intraday
-4.11%
1 week
-7.72%
1 month
-6.67%
1 year
66.67%
YTD
15.02%
QTD
-6.31%
Financial performance
How have Inozyme Pharma's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$92.89M
Net income
-$88.56M
Gross margin
N/A
Net margin
N/A
The company's net income fell by 30% YoY and by 15% QoQ
INZY's operating income is down by 30% year-on-year and by 14% since the previous quarter
Growth
What is Inozyme Pharma's growth rate over time
Valuation
What is Inozyme Pharma stock price valuation
P/E
N/A
P/B
3.21
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
INZY's EPS is down by 7% since the previous quarter but it is up by 6% year-on-year
The price to book (P/B) is 52% higher than the 5-year quarterly average of 2.2 and 29% higher than the last 4 quarters average of 2.6
The equity has declined by 21% since the previous quarter and by 11% year-on-year
Efficiency
How efficient is Inozyme Pharma business performance
The company's return on invested capital rose by 26% YoY but it fell by 9% QoQ
INZY's ROE is down by 17% since the previous quarter and by 17% year-on-year
The company's return on assets fell by 14% QoQ and by 3.2% YoY
Dividends
What is INZY's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for INZY.
Financial health
How did Inozyme Pharma financials performed over time
Inozyme Pharma's total assets is 154% higher than its total liabilities
The total liabilities rose by 35% YoY and by 5% QoQ
The quick ratio has contracted by 31% from the previous quarter and by 20% YoY
The company's debt is 51% lower than its equity
The debt to equity has soared by 53% YoY and by 26% from the previous quarter
The company's debt rose by 37% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.